asurgeryАмбулаторная хирургияAmbulatornaya khirurgiya = Ambulatory Surgery (Russia)2712-87412782-2591ООО «ГРУППА РЕМЕДИУМ»10.21518/akh2025-056asurgery-580Research ArticleФЛЕБОЛОГИЯPHLEBOLOGYФлеботропная терапия ранних форм хронических заболеваний вен: первый опыт клинического применения фиксированной комбинации на основе экстракта иглицы колючейPhlebotropic therapy for early chronic venous diseases: The first clinical experience with a fixed-dose Ruscus aculeatus extract combinationhttps://orcid.org/0000-0002-3940-0787БогачевВ. Ю.BogachevV. Yu.

Богачев Вадим Юрьевич, д.м.н., профессор, профессор кафедры хирургии, руководитель курса амбулаторной и эстетической флебологии факультета усовершенствования врачей, 129110, Москва, ул. Щепкина, д. 61/2, корп. 1;

научный руководитель, 117447, Москва, ул. Дмитрия Ульянова, д. 31

Vadim Yu. Bogachev, Dr. Sci. (Med.), Professor, Professor of the Department of Surgery, Head of the Course in Outpatient and Aesthetic Phlebology, Faculty of Advanced Medical Training, 61/2, Bldg. 1, Schepkin St., Moscow, 129110;

Scientific Supervisor, 31, Dmitry Ulyanov St., Moscow, 117447

vadim.bogachev63@gmail.comhttps://orcid.org/0000-0003-3811-5156ДженинаО. В.DzheninaO. V.

Дженина Ольга Вадимовна, к.м.н., врач-флеболог, ведущий специалист, 

117447, Москва, ул. Дмитрия Ульянова, д. 31

Olga V. Dzhenina, Cand. Sci. (Med.), Phlebologist, Leading Specialist,

31, Dmitry Ulyanov St., Moscow, 117447

helgelman@mail.ruhttps://orcid.org/0000-0002-9483-246XБогачеваН. В.BogachevaN. V.

Богачева Наталия Вадимовна, к.психол.н., доцент, заместитель директора по научной работе Института психолого-социальной работы,

119991, Москва, ул. Трубецкая, д. 8, стр. 2

Nataliya V. Bogacheva, Cand. Sci. (Psychol.), Associate Professor, Deputy Director for Science, Institute of Psychosocial and Social Work,

8, Bldg. 2, Trubetskaya St., Moscow, 119991

bogacheva.nataly@gmail.comhttps://orcid.org/0009-0009-0122-6523СавиноваМ. С.SavinovaM. S.

Савинова Мария Сергеевна, клинический ординатор кафедры хирургии факультета усовершенствования врачей,

129110, Москва, ул. Щепкина, д. 61/2, корп. 1

Mariia S. Savinova, Clinical Resident of the Department of Surgery, Faculty of Advanced Medical Training,

61/2, Bldg. 1, Schepkin St., Moscow, 129110

massav2002@mail.ruМосковский областной научно-исследовательский клинический институт имени М.Ф. Владимирского; Первый флебологический центрРоссияMoscow Regional Research Clinical Institute named after M.F. Vladimirsky; First Phlebological CenterRussian FederationПервый флебологический центрРоссияFirst Phlebological CenterRussian FederationПервый Московский государственный медицинский университет имени И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian FederationМосковский областной научно-исследовательский клинический институт имени М.Ф. ВладимирскогоРоссияMoscow Regional Research Clinical Institute named after M.F. VladimirskyRussian Federation2025251120252224657Copyright © Богачев В.Ю., Дженина О.В., Богачева Н.В., Савинова М.С., 20252025Богачев В.Ю., Дженина О.В., Богачева Н.В., Савинова М.С.Bogachev V.Y., Dzhenina O.V., Bogacheva N.V., Savinova M.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.a-surgeon.ru/jour/article/view/580Введение

Введение. Расширение ретикулярных вен (РВ) и телеангиоэктазии (ТАЭ) в чистом виде встречаются у 26% пациентов с хроническими заболеваниями вен (ХЗВ), преимущественно женского пола.

Цель

Цель. Оценить эффективность и безопасность нового флеботропного препарата Цикло 3® Форт (фиксированная комбинация экстракта корневищ иглицы колючей, гесперидина метилхалкона и аскорбиновой кислоты) для устранения веноспецифических симптомов у пациенток с начальными проявлениями венозной патологии (С0S и C1S по CEAP) в летний период.

Материалы и методы

Материалы и методы. Проведено открытое наблюдательное исследование с мая по сентябрь 2025 г. Рандомизировано 130 женщин в возрасте от 18 до 45 лет (средний возраст 32,2 ± 3,1 года). У 70 (53,8%) пациенток отмечались веноспецифические жалобы при отсутствии внешних или ультразвуковых признаков поражения вен, у 60 (46,2%) –расширенные РВ и ТАЭ на обеих нижних конечностях. Пациентки были распределены на две группы по 65 человек в каждой (35 – С0S + 30 – С1S). В 1-й группе назначена терапия препаратом Цикло 3® Форт, во 2-й группе даны рекомендации по коррекции образа жизни с возможностью использования чрескожных флебологических лекарственных препаратов. Общий период наблюдения составил 90 дней.

Результаты

Результаты. В 1-й группе у трети пациенток заболевание перестало идентифицироваться и было исключено из классификации CEAP, а у 25 (83,3%) женщин с классом С1S отмечен переход в клинический класс C1A по классификации СЕАР. Во 2-й группе переход заболевания из класса С0S в C0A наблюдался у 15 пациенток (42,9%), а из С1S в С1А – в 8 случаях (26,7%). По результатам фотоплетизмографии (ФПГ) в 1-й группе время возвратного кровенаполнения возросло с 22,4 ± 2,4 сек до 26,3 ± 1,2 сек, а сила мышечно-венозной помпы увеличилась с 3,9 ± 1,4% до 6,4 ± 1,1% (p < 0,001). Во 2-й группе показатели ФПГ остались без значимых изменений.

Заключение

Заключение. Продемонстрированы безопасность и эффективность применения препарата Цикло 3® Форт для снижения веноспецифической симптоматики при начальных формах ХЗВ и улучшения упруго-эластических свойств венозной стенки.

Introduction

Introduction. Reticular vein (RV) dilation and telangiectasia (TAE) in the pure form occur in 26% of patients with chronic venous diseases (CVD), mainly affecting female gender.

Aim

Aim. To evaluate the efficacy and safety of the novel phlebotropic drug Cyclo 3® Fort (a fixed-dose combination of Ruscus aculeatus extract, hesperidin methyl chalcone, and ascorbic acid) for the elimination of vein-specific symptoms in patients with initial presentations of venous pathology (CEAP C0S and C1S) in the summer months.

Materials and methods

Materials and methods. An open-label observational study was conducted in the period from May to September 2025. One hundred thirty women aged 18 to 45 years (mean age 32.2 ± 3.1 years) were randomly selected. Seventy female patients (53.8%) had venospecific complaints and no external or ultrasound imaging findings of vein injuries, while 60 (46.2%) had dilated reticular veins (RV) and transient ischemic attacks (TIA) in both lower limbs. The patients were divided into two groups of 65 patients each (35 with C0S and 30 with C1S). Group 1 received Cyclo 3® Fort, while Group 2 received lifestyle modification recommendations, including the use of percutaneous phlebological drugs. The total observation period was 90 days.

Results

Results. In Group 1, a third of patients did not exhibit any identifiable signs of the disease, which was excluded from the CEAP classification, while 25 (83.3%) women with class C1S transitioned to CEAP clinical class C1. In Group 2, disease transition from class C0S to C0A was observed in 15 patients (42.9%), and from C1S to C1A in 8 patients (26.7%). Photoplethysmography (PPG) results showed that in Group 1 the venous refilling time increased from (22.4 ± 2.4) seconds to (26.3 ± 1.2) seconds, and the calf muscle-venous pump performance increased from (3.9 ± 1.4) % to (6.4 ± 1.1) % (p < 0.001). In Group 2, PPG findings showed no significant changes.

Conclusion

Conclusion. The study demonstrated the safety and efficacy of Cyclo 3® Fort in reducing vein-specific symptoms at the initial stages of CVD and improving the elastic rebound properties of the venous wall.

флебопатииретикулярные венытелеангиоэктазиихронические заболевания венфлеботропные препаратыэкстракт иглицыгесперидин метилхалконаскорбиновая кислотаphlebopathyreticular veinstelangiectasiaschronic venous diseasesphlebotropic drugsbutcher's broom extracthesperidin methyl chalconeascorbic acidReferencesRabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974.Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global Epidemiology of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.Salim S, Machin M, Patterson BO, Onida S, Davies AH. Global Epidemiology of Chronic Venous Disease: A Systematic Review With Pooled Prevalence Analysis. Ann Surg. 2021;274(6):971–976. https://doi.org/10.1097/SLA.0000000000004631.Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–352. https://doi.org/10.1016/j.jvsv.2019.12.075.Lurie F, Passman M, Meisner M, Dalsing M, Masuda E, Welch H et al. The 2020 update of the CEAP classification system and reporting standards. J Vasc Surg Venous Lymphat Disord. 2020;8(3):342–352. https://doi.org/10.1016/j.jvsv.2019.12.075.Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg. 2009;49(2):498–501. https://doi.org/10.1016/j.jvs.2008.09.014.Eklof B, Perrin M, Delis KT, Rutherford RB, Gloviczki P. Updated terminology of chronic venous disorders: the VEIN-TERM transatlantic interdisciplinary consensus document. J Vasc Surg. 2009;49(2):498–501. https://doi.org/10.1016/j.jvs.2008.09.014.Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974/.Rabe E, Guex JJ, Puskas A, Scuderi A, Fernandez Quesada F. Epidemiology of chronic venous disorders in geographically diverse populations: results from the Vein Consult Program. Int Angiol. 2012;31(2):105–115. Available at: https://pubmed.ncbi.nlm.nih.gov/22466974/.Guex JJ, Rabe E, Escotto SI, Escudero JR, Scuderi A, Yuwono HS. The ‘‘C0s’’ patient: worldwide results from the Vein Consult Program. Phlebolymphology. 2012;19(4):182–192. Available at: https://www.phlebolymphology.org/the-c0s-patient-worldwide-results-fromthe-vein-consult-program/.Guex JJ, Rabe E, Escotto SI, Escudero JR, Scuderi A, Yuwono HS. The ‘‘C0s’’ patient: worldwide results from the Vein Consult Program. Phlebolymphology. 2012;19(4):182–192. Available at: https://www.phlebolymphology.org/the-c0s-patient-worldwide-results-fromthe-vein-consult-program/.Andreozzi G, Signorelli S, Di Pino L, Garozzo S, Cacciaguerra G, Leone A, Martini R. Varicose symptoms without varicose veins: the hypotonic phlebopathy, epidemiology and pathophysiology. The Acireale project. Minerva Cardioangiol. 2000;48(10):277–285. Available at: https://www.researchgate.net/publication/12134932_Varicose_symptoms_without_varicose_veins_The_hypotonic_phlebopathy_epidemiology_and_pathophysiology_The_acireale_project.Andreozzi G, Signorelli S, Di Pino L, Garozzo S, Cacciaguerra G, Leone A, Martini R. Varicose symptoms without varicose veins: the hypotonic phlebopathy, epidemiology and pathophysiology. The Acireale project. Minerva Cardioangiol. 2000;48(10):277–285. Available at: https://www.researchgate.net/publication/12134932_Varicose_symptoms_without_varicose_veins_The_hypotonic_ phlebopathy_epidemiology_and_pathophysiology_The_acireale_project.Serra R, Grande R, Butrico L, Fugetto F, De Franciscis S. Epidemiology, diagnosis and treatment of chronic venous disease: a systematic review. Chirurgia. 2016;29(2):34–45. Available at: https://www.minervamedica.it/en/journals/chirurgia/article.php?cod=R20Y2016N02A0034.Serra R, Grande R, Butrico L, Fugetto F, De Franciscis S. Epidemiology, diagnosis and treatment of chronic venous disease: a systematic review. Chirurgia. 2016;29(2):34–45. Available at: https://www.minervamedica.it/en/journals/chirurgia/article.php?cod=R20Y2016N02A0034.Serra R, Andreucci M, De Caridi G, Massara M, Mastroroberto P, de Franciscis S. Functional chronic venous disease: A systematic review. Phlebology. 2017;32(9):588–592. https://doi.org/10.1177/0268355516686451.Serra R, Andreucci M, De Caridi G, Massara M, Mastroroberto P, de Franciscis S. Functional chronic venous disease: A systematic review. Phlebology. 2017;32(9):588–592. https://doi.org/10.1177/0268355516686451.Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005;56(Suppl. 1):S11–S19. https://doi.org/10.1177/00033197050560i103.Nicolaides AN. Chronic venous disease and the leukocyte-endothelium interaction: from symptoms to ulceration. Angiology. 2005;56(Suppl. 1):S11–S19. https://doi.org/10.1177/00033197050560i103.Vital A, Carles D, Serise JM, Boisseau MR. Evidence for unmyelinated C fibres and inflammatory cells in human varicose saphenous vein. Int J Angiol. 2010;19(2):e73–e77. https://doi.org/10.1055/s-0031-1278374.Vital A, Carles D, Serise JM, Boisseau MR. Evidence for unmyelinated C fibres and inflammatory cells in human varicose saphenous vein. Int J Angiol. 2010;19(2):e73–e77. https://doi.org/10.1055/s-0031-1278374.Serra R, Gallelli L, Perri P, De Francesco EM, Rigiracciolo DC, Mastroroberto P et al. Estrogen Receptors and Chronic Venous Disease. Eur J Vasc Endovasc Surg. 2016;52(1):114–118. https://doi.org/10.1016/j.ejvs.2016.04.020.Serra R, Gallelli L, Perri P, De Francesco EM, Rigiracciolo DC, Mastroroberto P et al. Estrogen Receptors and Chronic Venous Disease. Eur J Vasc Endovasc Surg. 2016;52(1):114–118. https://doi.org/10.1016/j.ejvs.2016.04.020.Chiesa R, Marone EM, Limoni C, Volontè M, Petrini O. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg. 2007;46(2):322–330. https://doi.org/10.1016/j.jvs.2007.04.030.Chiesa R, Marone EM, Limoni C, Volontè M, Petrini O. Chronic venous disorders: correlation between visible signs, symptoms, and presence of functional disease. J Vasc Surg. 2007;46(2):322–330. https://doi.org/10.1016/j.jvs.2007.04.030.Богачев ВЮ. Гормоноиндуцированная флебопатия. Новая проблема современной флебологии. Ангиология и сосудистая хирургия. 2002;8(3):50–54. Режим доступа: https://www.angiolsurgery.org/magazine/2002/3/7.htm.Богачев ВЮ. Гормоноиндуцированная флебопатия. Новая проблема современной флебологии. Ангиология и сосудистая хирургия. 2002;8(3):50–54. Режим доступа: https://www.angiolsurgery.org/magazine/2002/3/7.htm. Bogachev VYu. Hormone-induced phlebopathy. A new problem of modern phlebology. Angiology and Vascular Surgery. 2002;8(3):50–54. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2002/3/7.htm.Цуканов ЮТ, Цуканов АЮ. Клиническая оценка тяжести флебопатии на основе детализации симптома тяжести. Ангиология и сосудистая хирургия. 2003;9(1):67–70. Режим доступа: https://www.angiolsurgery.org/magazine/2003/1/8.htm.Tsoukanov YuT, Tsoukanov AYu. Clinical assessment of phlebopathy severity by specification of leg heaviness symptom. Angiology and Vascular Surgery. 2003;9(1):67–70. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2003/1/8.htm.Цуканов ЮТ, Цуканов АЮ, Баженов ВН. Влияние оральных контрацептивов на магистральных диаметр вен нижних конечностей в ортостазе и их коррекция. Ангиология и сосудистая хирургия. 2008;14(1):75–77. Режим доступа: https://www.angiolsurgery.org/magazine/2008/1/10.htm.Tsukanov YuT, Tsukanov AYu, Bazhenov VN. The effect of oral contraceptives on the orthostatic diameter of lower limb major veins and its correction. Angiology and Vascular Surgery. 2008;14(1):75–77. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2008/1/10.htm.Цуканов ЮТ, Цуканов АЮ, Баженов ВН, Корниенко ИФ, Василевич ВВ. Медикаментозная коррекция негативных флеботропных эффектов гормонозаместительной терапии у женщин. Ангиология и сосудистая хирургия. 2009;15(3):87–91. Режим доступа: https://www.angiolsurgery.org/magazine/2009/3/13.htm.Tsukanov YuT, Tsukanov AYu, Bazhenov VN, Kornienko IF, Vasilevich VV. Drug-mediated correction of negative phlebotropic effects of hormone replacement therapy in women. Angiology and Vascular Surgery. 2009;15(3):87–91. (In Russ.) Available at: https://www.angiolsurgery.org/magazine/2009/3/13.htm.Sandean DP, Syed HA, Winters R. Spider Veins. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK563218/.Sandean DP, Syed HA, Winters R. Spider Veins. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025. Available at: https://www.ncbi.nlm.nih.gov/books/NBK563218/.Mansilha A, Sousa J. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy. Int J Mol Sci. 2018;19(6):1669. https://doi.org/10.3390/ijms19061669.Mansilha A, Sousa J. Pathophysiological Mechanisms of Chronic Venous Disease and Implications for Venoactive Drug Therapy. Int J Mol Sci. 2018;19(6):1669. https://doi.org/10.3390/ijms19061669.Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41(1):117–125. https://doi.org/10.1016/j.ejvs.2010.09.025.Perrin M, Ramelet AA. Pharmacological treatment of primary chronic venous disease: rationale, results and unanswered questions. Eur J Vasc Endovasc Surg. 2011;41(1):117–125. https://doi.org/10.1016/j.ejvs.2010.09.025.Rabe E, Agus G, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428–436. Available at: https://www.minervamedica.it/en/journals/international-angiology/article.php?cod=R34Y2015N05A0428.Rabe E, Agus G, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015;34(5):428–436. Available at: https://www.minervamedica.it/en/journals/international-angiology/article.php?cod=R34Y2015N05A0428.Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebocontrolled trials. Int Angiol. 2018;37(2):143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.Kakkos SK, Nicolaides AN. Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: a systematic review and meta-analysis of randomized double-blind placebocontrolled trials. Int Angiol. 2018;37(2):143–154. https://doi.org/10.23736/S0392-9590.18.03975-5.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of chronic venous disorders of the lower limbs. Guidelines According to Scientific Evidence. Part I. Int Angiol. 2018;37(3):181–254. https://doi.org/10.23736/S0392-9590.18.03999-8.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of Chronic Venous Disorders of the Lower Limbs. Guidelines According to Scientific Evidence. Part II. Int Angiol. 2020;39(3):175–240. https://doi.org/10.23736/S0392-9590.20.04388-6.Nicolaides A, Kakkos S, Baekgaard N, Comerota A, de Maeseneer M, Eklof B et al. Management of Chronic Venous Disorders of the Lower Limbs. Guidelines According to Scientific Evidence. Part II. Int Angiol. 2020;39(3):175–240. https://doi.org/10.23736/S0392- 9590.20.04388-6.Шайдаков ЕВ, Санников АБ. Фотоплетизмографическая характеристика эффективности работы мышечно-венозной помпы голени в норме и у пациентов с хроническими заболеваниями вен различных клинических классов (по СЕАР). Амбулаторная хирургия. 2021;18(1):103–119. https://doi.org/10.21518/1995-1477-2021-18-1-103-119.Shaydakov EV, Sannikov AB. Photoplethysmographic characteristics of the efficiency of the calf muscle-venous pump in norm and in patients with cvd of various clinical classes according to CEAP. Ambulatornaya Khirurgiya. 2021;18(1):103–119. (In Russ.) https://doi.org/10.21518/1995-1477-2021-18-1-103-119.Launois R, Mansilha A, Jantet G. International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20). Eur J Vasc Endovasc Surg. 2010;40(6):783–789. https://doi.org/10.1016/j.ejvs.2010.03.034.Launois R, Mansilha A, Jantet G. International psychometric validation of the Chronic Venous Disease quality of life Questionnaire (CIVIQ-20). Eur J Vasc Endovasc Surg. 2010;40(6):783–789. https://doi.org/10.1016/j.ejvs.2010.03.034.Kuet ML, Lane TR, Anwar MA, Davies AH. Comparison of disease-specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648–653. https://doi.org/10.1177/0268355513501302.Kuet ML, Lane TR, Anwar MA, Davies AH. Comparison of disease-specific quality of life tools in patients with chronic venous disease. Phlebology. 2014;29(10):648–653. https://doi.org/10.1177/0268355513501302.Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384. https://doi.org/10.1136/jech.52.6.377.Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998;52(6):377–384. https://doi.org/ 10.1136/jech.52.6.377.Мазайшвили КВ, Киян КА, Хлевтова ТВ, Цыплящук АВ, Суханов АВ, Ангелова ВА, Семкин ВД. Пациенты с С0S и C1S на амбулаторном приеме: следует ли думать о флебопатии? Флебология. 2016;(3):137–140. https://doi.org/10.17116/flebo2016103137-140.Mazayshvili KV, Kian RA, Khlevtova TV, Tsypliashuk AV, Suhanov AV, Angelova VA, Semkin VD. The Patient with C0S and C1S: Should a Phlebopathy Be Considered? Flebologiya. 2016;(3):137–140. (In Russ.) https://doi.org/10.17116/flebo2016103137-140.Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A. How specific are venous symptoms for diagnosis of chronic venous disease? Phlebology. 2014;29(9):580–586. https://doi.org/10.1177/0268355513515859.Van der Velden SK, Shadid NH, Nelemans PJ, Sommer A. How specific are venous symptoms for diagnosis of chronic venous disease? Phlebology. 2014;29(9):580–586. https://doi.org/10.1177/0268355513515859.Wrona M, Jöckel KH, Pannier F, Bock E, Hoffmann B, Rabe E. Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1. Eur J Vasc Endovasc Surg. 2015;50(3):360–367. https://doi.org/10.1016/j.ejvs.2015.05.013.Wrona M, Jöckel KH, Pannier F, Bock E, Hoffmann B, Rabe E. Association of Venous Disorders with Leg Symptoms: Results from the Bonn Vein Study 1. Eur J Vasc Endovasc Surg. 2015;50(3):360–367. https://doi.org/10.1016/j.ejvs.2015.05.013.Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;11(11):CD003229. https://doi.org/10.1002/14651858.CD003229.pub4.Martinez-Zapata MJ, Vernooij RW, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2020;11(11):CD003229. https://doi.org/10.1002/14651858.CD003229.pub4.Tsukanov Y, Nicolaichuk A. Changes in clinical manifestations and biophysical properties of the great saphenous vein in transient premenstrual phlebopathy after 12 months’ treatment with micronized purified flavonoid fraction. Phlebolymphology. 2020;27(1):36–42. Available at: https://www.phlebolymphology.org/changes-in-clinical-manifestations-and-biophysical-propertiesof-the-great-saphenous-vein-in-transient-premenstrual-phlebopathy-after-12-months-treatment-with-micronized-purifiedflavonoid-f.Tsukanov Y, Nicolaichuk A. Changes in clinical manifestations and biophysical properties of the great saphenous vein in transient premenstrual phlebopathy after 12 months’ treatment with micronized purified flavonoid fraction. Phlebolymphology. 2020;27(1):36–42. Available at: https://www.phlebolymphology.org/changes-in-clinical-manifestations-and-biophysical-propertiesof-the-great-saphenous-vein-in-transient-premenstrual-phlebopathy-after-12-months-treatment-with-micronized-purifiedflavonoid-f.De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.De Maeseneer MG, Kakkos SK, Aherne T, Baekgaard N, Black S, Blomgren L et al. Editor’s Choice – European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg. 2022;63(2):184–267. https://doi.org/10.1016/j.ejvs.2021.12.024.Апханова ТВ, Булатов ВЛ, Вахратьян ПЕ, Волков АМ, Волков АС, Гаврилов ЕК и др. Варикозное расширение вен нижних конечностей: клинические рекомендации. М.; 2024. 178 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/680_2.Апханова ТВ, Булатов ВЛ, Вахратьян ПЕ, Волков АМ, Волков АС, Гаврилов ЕК и др. Варикозное расширение вен нижних конечностей: клинические рекомендации. М.; 2024. 178 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/680_2.Богачев ВЮ, Болдин БВ, Комов КВ, Дженина ОВ. Фиксированные комбинации в фармакотерапии хронических заболеваний вен. Амбулаторная хирургия. 2024;21(2):44–51. https://doi.org/10.21518/akh2024-042.Bogachev VYu, Boldin VB, Komov KV, Dzhenina OV. Fixed-dose combinations in pharmacotherapy of chronic venous diseases. Ambulatornaya Khirurgiya. 2024;21(2):44–51. (In Russ.) https://doi.org/10.21518/akh2024-042.Богачев ВЮ, Болдин БВ, Комов КВ, Абдош Р, Копненкова ДК, Дженина ОВ. Фиксированная комбинация на основе экстракта рускуса и ее место в современных клинических рекомендациях по лечению хронических заболеваний вен. Амбулаторная хирургия. 2025;22(1):21–31. https://doi.org/10.21518/akh2025-023.Bogachev VYu, Boldin BV, Komov KV, Abdoch R, Kopnenkova DK, Dzhenina OV. Fixed-dose ruscus extract combi nation and its place in current clinical guidelines for the treatment of chronic venous diseases. Ambulatornaya Khirurgiya. 2025;22(1):21–31. (In Russ.) https://doi.org/10.21518/akh2025-023.

The authors declare that there are no conflicts of interest present.